Even otherwise healthy children can end up in hospital with this winter respiratory virus.
Academic rigor, journalistic flair
Articles on Monoclonal antibodies
Displaying 1 - 20 of 26 articles
In health care crises, researchers can avoid waiting for clinical trial results by using data from health care systems to analyze the effectiveness of treatments for COVID-19 and other illnesses.
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
In particular, a drug called Evusheld could offer protection for people who are vulnerable – but the UK isn’t offering it.
Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.
Face masks are still an effective way to help stop the spread of the BA.5 subvariant.
Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
Evusheld is an antibody drug from AstraZeneca intended to help prevent COVID-19 infection for immunocompromised and other vulnerable patients.
Although treatments for Ebola have helped many people overcome this deadly disease, the virus can persist in the brain and cause a lethal relapse.
Sotrovimab and baricitinib target COVID at different stages of its development, and will give doctors greater flexibility in treating omicron patients.
AstraZeneca’s durable monoclonal antibody treatment has shown promise in phase 3 clinical trials.
Medications to treat COVID-19 are in no way a substitute for the vaccine. But under the right circumstances, some show great promise for helping patients.
This lab-designed antibody treatment can treat COVID-19 and block infection, though its cost means it may be reserved for the most vulnerable.
The government has ordered 7,700 doses of sotrovimab. But until further evidence shows it’s effective, the guidelines say it should only be given to patients as part of a human clinical trial.
A year after it became clear that COVID-19 was becoming a pandemic, there is still no cure, but doctors have several innovative treatments. Some are keeping patients out of the hospital entirely.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Monoclonal antibodies are synthetic molecules manufactured in the lab. But do we need them if a vaccine is on its way?
The president and first lady Melania Trump have both tested positive for the coronavirus. Here’s what the physicians and scientists know about the best treatments for the disease it causes.
As grim as things are with the pandemic raging in the US and the mounting death toll, there are many reasons to be optimistic there will be a vaccine by early next year.
Vaccines and antivirals aren’t the only game in town.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Emeritus Professor, Brunel University London
-
Professor of Medicine, University of Virginia
-
Visiting Research Fellow, History of Biomedical Sciences, University of Cambridge
-
Regents' Professor & Chair, Medical Laboratory Science, Texas State University
-
Assistant Professor of Medicine, University of Pittsburgh
-
Assistant Professor of Neurology, University of Florida
-
Postdoctoral Researcher in the MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford
-
Assistant Professor of Medicine, University of Pittsburgh
-
Associate Professor of Medicine, Epidemiology and Clinical and Translational Science, University of Pittsburgh
-
Principal Investigator of Infectious Diseases, U.S. Army Medical Research Institute of Infectious Diseases
-
Professor of Medicine and Director, Center for Antibody Therapeutics, University of Pittsburgh
-
Paediatric Respiratory Physician, and Honorary Fellow Manager, Murdoch Children's Research Institute
-
Professor of Molecular Immunology, University of Oxford
-
Assistant Professor of Emergency Medicine, Albert Einstein College of Medicine
